Concepedia
Statistics
Publications
7
Citations
641
H-Index
Active since
2012
Affiliations
Cancer Research UK(Current)
AstraZeneca (United Kingdom)
The Christie NHS Foundation Trust
Cancer Research UK Manchester Institute
CRUK Lung Cancer Centre of Excellence
Mitchell Revill is an author at Cancer Research UK specializing in oncology, medicine, and pharmacology.
Publications per year
2012–2021
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 182 citations
Medicine, Oncology, Pharmacology +16
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn Simpson, Ruth Stoney, Kristopher K. Frese et al. · Nature Cancer · 2020 · 169 citations
Medicine, Cancer Biology, Oncology +12
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 158 citations · Full text
Medicine, Oncology, Pharmacology +13
The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report
Sarah M. Pearsall, Sam Humphrey, Mitchell Revill et al. · Journal of Thoracic Oncology · 2020 · 71 citations · Full text
Medicine, Cancer Biology, Oncology +16
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer
Maximilian W. Schenk, Sam Humphrey, A. S. Md Mukarram Hossain et al. · Nature Communications · 2021 · 25 citations · Full text
Medicine, Oncology, Pharmacology +15
1–5 of 7